David Spellman

Net worth: 593 822 $ as of 29/04/2024

48 year

Health Technology

Consumer Services

Former positions of David Spellman

Companies	Position	Start	End
AKEBIA THERAPEUTICS, INC.	Comptroller/Controller/Auditor	29/12/2022	22/06/2023
	Director of Finance/CFO	28/06/2020	22/06/2023
	Treasurer	28/06/2020	22/06/2023
Intarcia Therapeutics, Inc. Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.	Director of Finance/CFO	31/10/2019	28/06/2020
	Corporate Officer/Principal	31/05/2019	31/10/2019
MERSANA THERAPEUTICS, INC.	Director of Finance/CFO	11/03/2018	29/06/2019
VERTEX PHARMACEUTICALS INCORPORATED	Corporate Officer/Principal	-	-

The Wharton School of the University of Pennsylvania

Undergraduate Degree

International

United States

Operational

Director of Finance/CFO	3
Corporate Officer/Principal	2
Undergraduate Degree	1

Sectoral

Health Technology	5
Consumer Services	2

Positions held

Active

Inactive

Listed companies

Private companies

Listed companies	3
VERTEX PHARMACEUTICALS INCORPORATED	Health Technology
MERSANA THERAPEUTICS, INC.	Health Technology
AKEBIA THERAPEUTICS, INC.	Health Technology

Private companies	1
Intarcia Therapeutics, Inc. Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.	Health Technology

Private companies

Health Technology